Bile Acid-Activated Receptors, Intestinal Microbiota, and the Treatment of Metabolic Disorders

Trends in Molecular Medicine

Volumn 21, Issue 11, 2015, Pages 702-714

  Fiorucci, Stefano ^a   Distrutti, Eleonora ^b  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AGENTS AFFECTING METABOLISM; BILE ACID; BILE ACID ACTIVATED RECEPTOR; FARNESOID X RECEPTOR; G PROTEIN COUPLED BILE ACID RECEPTOR 1; G PROTEIN COUPLED RECEPTOR; ISOXAZOLE DERIVATIVE; OBETICHOLIC ACID; PROBIOTIC AGENT; PX 104; RECEPTOR; RETINOID X RECEPTOR; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR; GPBAR1 PROTEIN, HUMAN;

BARIATRIC SURGERY; BILE ACID METABOLISM; BILE ACID SYNTHESIS; DIABETES MELLITUS; FATTY LIVER; HUMAN; INFLAMMATION; INTESTINE FLORA; METABOLIC DISORDER; MICROBIAL METABOLISM; MULTICENTER STUDY (TOPIC); NONHUMAN; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; METABOLISM; MICROBIOLOGY; PROCEDURES;

BARIATRIC SURGERY; BILE ACIDS AND SALTS; DIABETES MELLITUS; GASTROINTESTINAL MICROBIOME; HUMANS; INFLAMMATION; OBESITY; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION;

EID: 84947610783     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2015.09.001     Document Type: Review

References (73)

1. Sellayah D., et al. On the evolutionary origins of obesity: a new hypothesis. Endocrinology 2014, 155:1573-1588.
2. Nicholson J.K., et al. Gut microbiome-host co-development and metabolic interactions in health and disease. Science 2012, 336:1262-1267.
3. Human Microbiome Project, Consortium Structure, function and diversity of the healthy human microbiome. Nature 2012, 486:207-214.
4. Ley R.E., et al. Microbial ecology: human gut microbes associated with obesity. Nature 2006, 444:1022-1023.
5. Qin J., et al. A human gut microbial gene catalogue established by metagenomics sequencing. Nature 2010, 464:59-65.
6. De Vadder F., et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014, 156:84-96.
7. reg cell homeostasis. Science 2013, 341:569-573.
8. Furusawa Y., et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013, 504:446-450.
9. Langille M.G., et al. Predictive functional profiling of microbial communities using 16S rRNA marker gene sequences. Nat. Biotechnol. 2013, 31:814-821.
10. Li J., et al. An integrated catalog of reference genes in the human gut microbiome. Nat. Biotechnol. 2014, 32:834-841.
11. Li K., et al. Analyses of the stability and core taxonomic memberships of the human microbiome. PLoS ONE 2013, 8:e63139.
12. Lee S.M., et al. Bacterial colonization factors control specificity and stability of the gut microbiota. Nature 2013, 501:426-429.
13. Clemente J.C., et al. The impact of the gut microbiota on human health: an integrative view. Cell 2012, 148:1258-1270.
14. Arumugam M., et al. Enterotypes of the human gut microbiome. Nature 2011, 473:174-180.
15. Chiang J.Y. Bile acids: regulation of synthesis. J. Lipid Res. 2009, 50:1955-1966.
16. Wang L., et al. Redundant pathways for negative feedback regulation of bile acid production. Dev. Cell 2002, 2:721-731.
17. Goodwin B., et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 2000, 6:517-526.
18. Inagaki T., et al. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:3920-3925.
19. Makishima M., et al. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
20. Grober J., et al. Identification of a bile acid-responsive element in the human ileal bile acid-binding protein gene. Involvement of the farnesoid X receptor/9-cis-retinoicacid receptor heterodimer. J. Biol. Chem. 1999, 274:29749-29754.
21. Ridlon J.M., et al. Bile salt biotransformations by human intestinal bacteria. J. Lipid Res. 2006, 47:241-259.
22. Saini S.P., et al. A novel constitutive androstane receptor-mediated and CYP3A-independent pathway of bile acid detoxification. Mol. Pharmacol. 2004, 65:292-300.
23. Staudinger J.L., et al. The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:3369-3374.
24. Song C., et al. Selective activation of liver X receptor alpha by 6alpha-hydroxy bile acids and analogs. Steroids 2000, 65:423-427.
25. Makishima M., et al. Vitamin D receptor as an intestinal bile acid sensor. Science 2002, 296:1313-1316.
26. Kawamata Y., et al. A G protein-coupled receptor responsive to bile acids. J. Biol. Chem. 2003, 278:9435-9440.
27. Katsuma S., et al. Bile acids promote glucagon-like peptide-1 secretion through TGR5 in a murine enteroendocrine cell line STC-1. Biochem. Biophys. Res. Commun. 2005, 329:386-390.
28. Raufman J.P., et al. Deoxycholic acid conjugates are muscarinic cholinergic receptor antagonists. Pharmacology 2002, 65:215-2121.
29. Studer E., et al. Conjugated bile acids activate the sphingosine-1-phosphate receptor 2 in primary rodent hepatocytes. Hepatology 2012, 55:267-276.
30. Parks D.J., et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284:1365-1368.
31. Wang H., et al. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 1999, 3:543-553.
32. Kullak-Ublick G.A., et al. Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 2004, 126:322-342.
33. Watanabe M., et al. Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature 2006, 439:484-489.
34. Sayin S.I., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013, 17:225-235.
35. Li F., et al. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat. Commun. 2013, 4:2384.
36. Mencarelli A., et al. VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS ONE 2012, 7:e45425.
37. Mencarelli A., et al. Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS ONE 2011, 6:e22978.
38. Distrutti E., et al. Modulation of intestinal microbiota by the probiotic VSL#3 resets brain gene expression and ameliorates the age-related deficit in LTP. PLoS ONE 2014, 9:e106503.
39. Degirolamo C., et al. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep. 2014, 7:12-18.
40. Vavassori P., et al. The bile acid receptor FXR is a modulator 1of intestinal innate immunity. J. Immunol. 2009, 183:6251-6261.
41. Cipriani S., et al. The bile acid receptor GPBAR-1 (TGR5) modulates integrity of intestinal barrier and immune response to experimental colitis. PLoS ONE 2011, 6:e25637.
42. Islam K.B., et al. Bile acid is a host factor that regulates the composition of the cecal microbiota in rats. Gastroenterology 2011, 141:1773-1781.
43. Ridlon J.M., et al. Cirrhosis, bile acids and gut micro biota: unraveling a complex relationship. Gut Microbes 2013, 4:382-387.
44. Dubberke E.R., Olsen M.A. Burden of Clostridium difficile on the healthcare system. Clin. Infect. Dis. 2012, 55(Suppl. 2):S88-S92.
45. Sofi A.A., et al. Relationship of symptom duration and fecal bacteriotherapy in Clostridium difficile infection-pooled data analysis and a systematic review. Scand. J. Gastroenterol. 2013, 48:266-273.
46. Buffie C.G., et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2015, 512:205-208.
47. Miyata M., et al. Administration of ampicillin elevates hepatic primary bile acid synthesis through suppression of ileal fibroblast growth factor 15 expression. J. Pharmacol. Exp. Ther. 2009, 331:1079-1085.
48. Kaddurah-Daouk R., et al. Enteric microbiome metabolites correlate with response to simvastatin treatment. PLoS ONE 2011, 6:e25482.
49. Ridaura V.K., et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science 2013, 341:1241214.
50. Le Chatelier E., et al. Richness of human gut microbiome correlates with metabolic markers. Nature 2013, 500:541-546.
51. Risstad H., et al. Five-year outcomes after laparoscopic gastric bypass and laparoscopic duodenal switch in patients with body mass index of 50 to 60: a randomized clinical trial. JAMA Surg. 2015, 150:352-361.
52. Furet J.P., et al. Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes 2010, 59:3049-3057.
53. Graessler J., et al. Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics J. 2012, 13:514-522.
54. Salehi M., et al. Gastric bypass surgery enhances glucagon-like peptide 1-stimulated postprandial insulin secretion in humans. Diabetes 2011, 60:2308-2314.
55. Ryan K.K., et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 2014, 509:183-188.
56. Flynn C.R., et al. Bile diversion to the distal small intestine has comparable metabolic benefits to bariatric surgery. Nat. Commun. 2015, 6:7715.
57. Mencarelli A., et al. Dissociation of intestinal and hepatic activities of FXR and LXRα supports metabolic effects of terminal ileum interposition in rodents. Diabetes 2013, 62:3384-3393.
58. Lee J.M., et al. Nutrient-sensing nuclear receptors coordinate autophagy. Nature 2014, 516:112-115.
59. Seok S., et al. Transcriptional regulation of autophagy by an FXR-CREB axis. Nature 2014, 516:108-111.
60. Sepe V., et al. Steroidal scaffolds as FXR and GPBAR1 ligands: from chemistry to therapeutical application. Future Med. Chem. 2015, 7:1109-1135.
61. Chalasani N., et al. The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012, 55:2005.
62. Fiorucci S., et al. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. Mini Rev. Med. Chem. 2011, 11:753-762.
63. Neuschwander-Tetri B.A., et al. Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015, 385:956-965.
64. Hirschfield G.M., et al. Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology 2014, 148:751-761.
65. Cipriani S., et al. Impaired itching perception in murine models of cholestasis is supported by dysregulation of GPBAR1 signaling. PLoS ONE 2015, 10:e0129866.
66. Fiorucci S., et al. Targeting FXR in cholestasis: hype or hope. Expert Opin. Ther. Targets 2014, 18:1449-1459.
67. Mueller M., et al. Ursodeoxycholic acid exerts farnesoid x receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. J. Hepatol. 2015, 62:1398-1404.
68. Fang S., et al. Intestinal FXR agonism promotes adipose tissue browning and reduces obesity and insulin resistance. Nat. Med. 2015, 21:159-165.
69. Osório J. Obesity: gut-specific FXR agonism. Nat. Rev. Endocrinol. 2015, 11:131.
70. Jiang C., et al. Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. J. Clin. Invest. 2015, 125:386-402.
71. Zhou X., et al. PPAR(-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis. Nat. Commun. 2014, 5:4573.
72. Festa C., et al. Exploitation of cholane scaffold for the discovery of potent and selective farnesoid X receptor (FXR) and G-protein coupled bile acid receptor 1 (GP-BAR1) ligands. J. Med. Chem. 2014, 57:8477-8495.
73. Sepe V., et al. Modification on ursodeoxycholic acid (UDCA) scaffold. discovery of bile acid derivatives as selective agonists of cell-surface G-protein coupled bile acid receptor 1 (GP-BAR1). J. Med. Chem. 2014, 57:7687-7701.